Here’s what you should know.
1. Founding partner Nadeem Faruqi is leading the investigation of potential breaches of fiduciary duties in advance of the company’s sale to Takeda. Pharmaceutical Processing reports the investigation is largely centered around whether Ariad executives practiced fair sales processes.
2. The company’s stockholders are set to receive $24 for every share of Ariad’s stock they hold.
Mr. Faruqi is investigating if this valuation undervalues the company, and, if it does, by how much.
3. Takeda is primarily acquiring Ariad’s leukemia drug, Iclusig. Takeda expects the drug to generate between $170 million to $180 million in sales.
More articles on gastroenterology/endoscopy:
Drs. Rusha Modi, Steven M. Schwarz & more — 3 GI physicians in the headlines
GI leader to know: Dr. Shekhar Challa of Kansas Medical Clinic
GI leader to know: Dr. Mark Anderson of Boice-Willis Clinic
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
